Quality of life and seizure control in patients with brain tumor-related epilepsy treated with levetiracetam monotherapy: Preliminary data of an open-label study

Loredana Dinapoli, Marta Maschio, Bruno Jandolo, Alessandra Fabi, Andrea Pace, Francesca Sperati, Paola Muti

Research output: Contribution to journalArticle


The aim of this pilot study was to investigate the effects of levetiracetam monotherapy on seizure control, quality of life and neurocognitive performance in patients with brain tumor-related epilepsy. We present here preliminary data from 18 patients with follow-up of 6 months. We evaluated seizure frequency at baseline. We used administered Mini Mental State Examination (MMSE), Karnofsky Performance Status (KPS), Barthel index (BI), QOLIE 31P (V2), EORTC QLQ-C30 and Adverse Events Profile. After 6 months, 16 patients were seizure free (88.9%), 2 (11.1%) had reduction in seizure frequency >50%. Compared to baseline, we observed a worsening of performance (KPS p = 0.011; BI = 0.008) and global lower cognitive performance (MMSE p = 0.011); distress related to seizure frequency (p = 0.003) and medication effects (p = 0.046) were significantly lower. Levetiracetam caused mild and reversible side effects. These preliminary data on LEV monotherapy in patients with brain tumor-related epilepsy show that this antiepileptic drug is efficacious and well tolerated.

Original languageEnglish
Pages (from-to)353-359
Number of pages7
JournalNeurological Sciences
Issue number4
Publication statusPublished - 2009



  • Brain tumor-related epilepsy
  • Efficacy
  • Levetiracetam
  • Quality of life

ASJC Scopus subject areas

  • Clinical Neurology
  • Psychiatry and Mental health
  • Dermatology

Cite this